About GeneIII
GeneIII is a Healthcare company based in Nanjing (China) founded in 2021. GeneIII was founded in 2021 in Nanjing, China. GeneIII has raised $13.76 million across 1 funding round from investors including JAFCO Asia. GeneIII offers products and services including Ergothioneine (EGT) and Skincare and Supplement Applications. Its focus areas include Cosmeceuticals. Its legal entity in India is ζ±θδ» δΈηη©η§ζζιε ¬εΈ (U99999MH1977PLC010754).
Company details
GeneIII was established in 2021 and is located in Nanjing, China. The company operates within the biotechnology sector, as indicated by its name and domain geneiii.com.cn. Operations are based in China, with a focus on genetic-related activities inferred from the branding. Specific services and detailed business scope are not outlined in available data, positioning it as an emerging entity in the regional biotech landscape.
- Headquarters Nanjing, China
- SectorsHealthcare
- Website geneiii.com.cn
- Legal Name 江苏仅三生物科技有限公司
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
- Total Equity Funding$13.76M (USD)
in 1 rounds
- Latest Funding Round$13.76M (USD), Seed
Apr 2025
- Investors
Associated legal entities of GeneIII
GeneIII operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of GeneIII
GeneIII offers a comprehensive portfolio of products and services, including Ergothioneine (EGT) and Skincare and Supplement Applications.
Ergothioneine is produced as an antioxidant raw material for health and beauty applications
Applications of Ergothioneine are supplied for oral capsules and skincare formulations
Funding Insights of GeneIII
GeneIII has successfully raised a total of $13.76M through 1 strategic funding round. The most recent funding activity was a Seed round of $13.76 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.76M
- Total Rounds 1
- Last Round Seed β $13.76M
- First Round $13.76M
(Apr 2025)
- Investors Count 1
All 1 funding rounds of GeneIII with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $13.76M | Seed | β | JAFCO Asia | β |
1 investors in total: 1 institutional.
Investors in GeneIII
GeneIII has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include JAFCO Asia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in early-stage tech startups are made by JAFCO Asia. | jafcoasia.com | Singapore, Singapore |
Investor details for GeneIII
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GeneIII
2 dated milestones of GeneIII across 4 years, from founding to its latest funding, stage changes and deals.
- Founded GeneIII is founded.
- Funding First funding round of $13.8M.
Web traffic of GeneIII
The website of GeneIII (geneiii.com.cn) receives about 4.6K visits a month.
- Monthly visits4.6K
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Geneiii
Complete news archive for GeneIII
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GeneIII
GeneIII was founded in 2021 and raised its 1st funding round 4 years after it was founded.
GeneIII is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
GeneIII is a funded company, having raised a total of $13.76M across 1 funding round to date. The company's 1st funding round was a Seed of $13.76M, raised on Apr 2025.
GeneIII was established in 2021 and is located in Nanjing, China. The company operates within the biotechnology sector, as indicated by its name and domain geneiii.com.cn. Operations are based in China, with a focus on genetic-related activities inferred from the branding. Specific services and detailed business scope are not outlined in available data, positioning it as an emerging entity in the regional biotech landscape.
GeneIII offers Ergothioneine (EGT) and Skincare and Supplement Applications.
GeneIII has 1 investor. Key investors include JAFCO Asia.
GeneIII operates through ,.

